Study Evaluating Etanercept on Skin and Joint Disease in Psoriatic Arthritis
Psoriatic Arthritis
About this trial
This is an interventional treatment trial for Psoriatic Arthritis focused on measuring Psoriatic Arthritis, Skin Disease, Joint Disease
Eligibility Criteria
Inclusion Criteria: Inclusion Criteria: 18 years of age or older at time of consent Active Psoriatic Arthritis Clinically stable, plaque psoriasis involving more than 10% of the body surface area Exclusion Criteria: Exclusion Criteria: Evidence of skin conditions other than psoriasis that would interfere with skin examinations. Systemic anti-psoriasis therapy or DMARD within 28 days of study drug initiation Prior exposure to any TNF-inhibitor, including etanercept
Sites / Locations
- Hospital A Posadas
- Hospital General de Agudos
- Hospital Italiano de Buenos Aires
- CEMIC
- Hospital General de Agudos
- Hospital Italiano de Buenos Aires
- Instituto de Medicina Cutanea
- Goulburn Street Medical Centre
- St Vincent's Hospital VIC
- Universitaetsklinik Graz
- Krankenhaus Rudolfsstiftung
- Universitair Ziekenhuis Gent
- CHU Liege
- Centro Integral de Reumatologia del Caribe S.A.S
- Centro Medico de la Sabana
- Centrum Rehabilitace
- Revmatologicky ustav
- Revmatologicka Ambulance
- Bispebjerg University Hospital
- Gentofte University Hospital
- Hørsholm hospital
- Odense University Hospital
- University of Copenhagen - Roskilde Hospital
- Mehiläinen Terveyspalvelut Oy Forum
- Tampereen Reumatoismisto
- Iho ja Allergiapulssi
- Institute of Rheumatology Belgrade
- Institute of Rheumatology Niska Banja
- Clinic for Dermatology and Clinic for Medical Rehabilitation
- Clinical Center Zemun
- Centre Hospitalier du Mans
- Hôpital Saint André
- CHU - Hôpital Morvan
- C.H.R.U. de Caen
- Hôpital Henri Mondor
- CHU Dupuytren
- CHU de l Archet
- Hopital Saint Louis
- Hôpital Bichat - Claude Bernard
- Centre Hospitalier Lyon Sud
- CHU La Milétrie
- CHU - Hopital Charles Nicolle
- CHRU- Hôpital Trousseau
- Fachklinik Bad Bentheim
- Klinik fuer Dermatologie, Venerologie und Allergologie
- Schonhauser Allee 71
- Hautarztpraxis Dr. Margrit Simon
- Klinische Forschung Berlin-Buch GmbH
- Schlossparkklinik Berlin
- Klinik und Poliklinik für Dermatologie der Friedrich-Wilhelm
- Universitätsklinikum Hartmmannstrasse 14 Erlangen 91052
- Klinikum der J.W. Goethe-Universitat
- Georg-August Universitaet Goettingen
- Allgemeines Krankenhaus Eilbek
- SCIderm GmbH Hamburg
- Friedrich-Schiller Universitat Jena
- Friedrich-Schiller Universitat Jena
- Bahnhofstr. 1
- Klinikum Innenstadt der Universitaet Muenchen
- Klinikum Innenstadt der Universitaet Muenchen
- Dermatologische Gemeinschaftspraxis Rosenbach
- Praxis Dr. M. Richter
- Universitaetsklinik Wuerzburg
- Universitaetsklinik Wuerzburg
- University of Athens Andreas Syngros Hospital Athens, Greece
- Semmelweis University - Faculty of Health Sciences
- Debreceni Egyetem Orvos és Egészségtudományi Centrum
- Miskolc Megyei Jogu Varos Onkormanyzata, Miskolci Egeszsegui
- Pecsi Tudomanyegyetem, AOK
- Medical University of Szeged
- HETENYI Geza Hospital
- Azienda Ospedaliera Spedali Civili di Brescia
- Ospedale San Giovanni di Dio
- Clinica Dermatologica
- Ospedale Galeazzi
- Universita degli Studi di Parma
- Policlinico Umberto I - Universita La Sapienza
- Idi-Irccs
- Universita degli Studi di Siena
- Seoul National University Hospital
- Asan Medical Centre
- Unidad de Investigacion en
- CLIDITER S.A. de C.V.
- University Medical Center St. Radboud
- Academisch Ziekenhuis Maastricht
- Academisch Ziekenhuis Maastricht
- Ziekenhuis Walcheren
- Diaconessenhuis Voorburg
- Akad. Medyczna im L. Rydygiera
- Samodzielny Publiczny Szpital Kliniczny nr 4
- Wojskowy Instytut Medyczny
- Zesp. Naukowo-Kliniczny IWOLANG, Uzdrowiskowa Klinika Dermat
- Hospitais Da Universidade De Coimbra
- Hospital Santo Antonio
- King Faisal Specialist Hospital & Research Centre
- Hospital Universitario Puerto Real
- Hospital de Donostia
- Hospital Insular de Canarias
- Hospital Severo Ochoa de Leganes
- Hospital Nuestra Senora Del Mar
- Hospital de la Santa Cruz y San Pablo
- Hospital Ramon y Cajal
- Länssjukhuset Ryhov
- Umeå University Hospital
- Akademiska Sjukhuset i Uppsala
- CHUV Lausanne
- Universitatsspital Zurich
- Chang Gung Memorial Hospital-Kaohsiung
- National Taiwan University Hospital
- Hacettepe University Medicine Faculty
- The Royal Free Hospital, Pond Street, Hampstead
- Hope Hospital
- Harrogate District Hospital
- Leeds General Infirmary, Leeds
- Aberdeen Royal Infirmary
- University Hospital of Wales
- University Hospital of Wales
- The Royal Free Hospital, Pond Street, Hampstead
- Guy's and St. Thomas' Trust St.Thomas' Hospital
- George Elliott Hospital
Arms of the Study
Arm 1
Arm 2
Active Comparator
Active Comparator
A
B
Period 1 (Double Blind): 50mg bi-weekly (BIW) for weeks 1-12. Period 2 (Open Label): 50 mg weekly (QW).
Period 1 (Double Blind): 50mg weekly (QW) with matching placebo for weeks 1-12. Period 2 (Open Label): 50 mg weekly (QW) for weeks 13-24.